Online inquiry

IVTScrip™ mRNA-Anti-FZD7, FZD8-Fc(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (CAT#: GTTS-WQ7374MR)

This product GTTS-WQ7374MR is a type of mRNA modified with N1-Methylpseudo-UTP, which ecodes the monoclonal antibody that targets FZD7 gene. The antibody can be applied in Solid tumors research.

Specifications
Product type	mRNA
Modified bases	N1-Methylpseudo-UTP
5' Cap	Cap 1
Species	Homo sapiens
RefSeq	NM_003507.2
Applications	Gene therapy research
Format	Powder
Quantity	100 µg
Purification	oligo-dT affinity purification

Target Gene
Gene ID	8324
UniProt ID	O75084

Download
Download resources about mRNA therapeutics development to boost your research.

CUSTOMER REVIEWS and Q&As
There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-FZD7, FZD8-Fc(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ7374MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT	Product Name	Product Type	CDs
GTTS-WQ4926MR	IVTScrip™ mRNA-Anti-TNFRSF17, C11D5.3 scFv-8A-F9Z CAR(Cap 1, 2-Thio-UTP, 30 nt-poly(A))	mRNA	C11D5.3 scFv-8A-F9Z CAR
GTTS-WQ13338MR	IVTScrip™ mRNA-Anti-PDCD1, PF-06801591(Cap 1, Pseudo-UTP, 120 nt-poly(A))	mRNA	PF-06801591
GTTS-WQ2885MR	IVTScrip™ mRNA-Anti-CCR4, AMG-761(Cap 0, 2-Thio-UTP, 30 nt-poly(A))	mRNA	AMG-761
GTTS-WQ2966MR	IVTScrip™ mRNA-Anti-IL33, ANB020(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))	mRNA	ANB020
GTTS-WQ11254MR	IVTScrip™ mRNA-Anti-CD274, MEDI4736(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A))	mRNA	MEDI4736
GTTS-WQ2119MR	IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, Alb-IFNA2 R23 (608)(Cap 0, 5-Methyl-CTP, 120 nt-poly(A))	mRNA	Alb-IFNA2 R23 (608)
GTTS-WQ15196MR	IVTScrip™ mRNA-Anti-TNF, TA-650(Cap 1, 2-Thio-UTP, 120 nt-poly(A))	mRNA	TA-650
GTTS-WQ3958MR	IVTScrip™ mRNA-Anti-CD3E&FCRL5, BFCR-4350-A(Cap 1, Pseudo-UTP, 120 nt-poly(A))	mRNA	BFCR-4350-A

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST